Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilized liposomes
โ Scribed by Jan Vaage; Dorothy Donovan; Eric Mayhew; Paul Uster; Martin Woodle
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- French
- Weight
- 431 KB
- Volume
- 54
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
The purpose of our study was to compare the therapeutic effects of doxorubicin in 3 different formulations: (I) in PBS, (2) in conventional liposomes composed of egg phosphatidylglycerol/ egg phosphatidylcholine/cholesterol/dl-a tocopherol, and (3) in sterically stabilized, long-circulating "Stealth
Background. This study compared the therapeutic effects of doxorubicin hydrochloride in saline and in sterically stabilized, long-circulating liposomes composed of hydrogenated soy phosphatidylcholine/cholesteroljpolyethylene glycol-distearoyl-phosphatidyl-ethanolamine (Doxil]. Methods. The drug fo
Vincristine is used clinically for the treatment of various types of cancer. Recent significant therapeutic improvements obtained by entrapping anthracyclines in sterically stabilized liposomes raised the question whether the therapeutic index of vincristine can be similarly increased by formulation
Monthly treatments with intravenous doxorubicin encapsulated in long circulating, sterically stabilized liposomes delayed the appearance of primary mammary carcinomas and reduced the final incidence from 49 in 50 untreated mice to 46 in 87 treated mice. No toxic side effects of the treatments were o